Key result
Circulating microRNAs, including miR-132, miR-140-3p, and miR-210, show promise as biomarkers for predicting cardiovascular death with an area under the curve of 0.74-0.76.
Why the study?
Do circulating microRNA biomarkers improve cardiovascular risk prediction compared to current models?
Do circulating microRNA biomarkers improve cardiovascular risk prediction compared to current models?
Answers are grounded in this paper and cite their sources.
Circulating microRNAs show potential as biomarkers for predicting coronary artery disease and cardiovascular death, but require large-scale external validation before clinical implementation.
A range of circulating microRNA biomarkers for cardiovascular risk prediction is showing potential, Mark Nicholls reports While standard risk prediction models for cardiovascular disease have helped identify individuals vulnerable to a coronary event, it is becoming clear that circulating biomarkers are needed to help take that risk identification strategy on to the next level of accuracy. It is, however, only more recently that the potential of circulating microRNAs is being recognized and harnessed in this respect. Now, Amsterdam-based researchers are suggesting that some of the circulating microRNAs—short non-coding RNAs that post-transcriptionally regulate gene expression—have reached the stage where they may be ready for the next step toward clinical application. The research has been led by Dr Maurice de Ronde, PhD-student Vascular Medicine and Clinical Epidemiologist, and Dr Sara-Joan Pinto-Sietsma, Vascular Internist and Clinical Epidemiologist, at the Academic Medical Centre in Amsterdam. Dr de Ronde said: ‘Over the past few years, circulating microRNAs have been investigated as biomarkers for the risk prediction of many types and stages of cardiovascular disease, such as the prediction of coronary artery disease (CAD) in general, or to be able to identify more specific coronary artery disease types such as stable angina, unstable angina or myocardial infarctions. In total, >100 different circulating microRNAs have been associated with coronary artery disease.’ Of these, approximately 10 show potential in risk prediction as they have been implicated in CAD in more than two independent cohorts and are considered to have ‘many potential applications in future clinical care.’ While acknowledging ‘many ways to discover’ circulating microRNAs for CAD, the Amsterdam group used a high throughput microarray approach and analysed all known microRNAs in cohorts in their search for microRNA biomarkers for CAD. ‘Those microRNAs that were significantly different in expression between individuals with coronary artery disease vs. healthy controls were considered candidates’, he said. ‘Since there is still a relatively large false discovery rate, because of the small sample size and many possible outcomes, subsequent candidates should be validated and revalidated in several independent larger cohorts to confirm their association and robustness to CAD.’ The microRNAs they suggest are showing most potential are miR-155-5p, 126-3p and miR-146a-5p, which seem ‘to be most consistently, positively associated with coronary artery disease in at least three or more independent studies, described in reviews’. Concerning the prediction of cardiovascular death, a recent study published in the European Heart Journal1 assessed the predictive value of circulating microRNAs that were previously shown to be associated with the acute phase of unstable angina in three independent cohorts. The authors found that miR-132, miR-140-3p and miR-210 showed a strong association with cardiovascular death with area under the curve (AUC) of 0.74–0.76. ‘Therefore, these microRNAs propose to be promising biomarkers for coronary artery disease and death, since they have been implicated in these diseases in multiple studies and show relatively high predictive values,’ said Dr de Ronde. However, they warn that with microRNA biomarker research proving costly, many researchers use small sample sizes and risk a false discovery rate. This has led the researchers to stress that care should be taken with single discovery studies, in which multiple validation analysis has not yet been performed. ‘This very important issue complicates the decision on which microRNAs are the appropriate candidates for further development. We therefore believe that for accurate diagnosis of coronary artery disease the selection of candidate microRNAs should be made on the fact that discovery results are replicated in at least three larger external populations,’ added Dr de Ronde. ‘Therefore, the above-mentioned microRNAs show potential, since they fulfil these criteria. However, further external validation should be performed in even larger cohorts, before clinical application can be considered.’ With the ±10 miRNA biomarkers found to be associated to CAD, the Amsterdam team say now is the time to validate these miRNAs in larger studies to confirm their role in CAD and to assess their predictive value to decide whether they have a role in clinical practice. But they also warn that large scale clinical implementation of microRNA biomarkers in clinical practice will still take several years. So, how do they compare with current risk prediction models? Current risk prediction models predict cardiovascular risk with AUC between 0.6 and 0.8. Thus, the microRNAs miR-132, miR-140-3p and miR-210, have predictive values that are comparable to the current risk prediction models. ‘These microRNAs for coronary artery disease risk prediction have not been validated in external populations yet and therefore their AUCs may be overestimated,’ said Dr Pinto-Sietsma. ‘On the other hand these microRNAs are presumed to be independent of age, since they were designed to identify the atherosclerotic process itself, which is a huge advantage compared to the current risk prediction models, which are mainly driven by age, making these prediction models inaccurate, especially for young individuals.’ She said circulating microRNAs do have the potential to advance cardiovascular diagnosis and treatment. ‘Because microRNAs have a completely different approach of identifying coronary artery disease compared to the current risk prediction models, microRNAs can improve the risk prediction when added to the current risk prediction models,’ she said. ‘Besides, not only can microRNAs add in the early identification of individuals at risk, they may also help distinguish subgroups of coronary artery disease patients at risk of, for instance, unstable angina and hereby prevent the adverse effects of a myocardial infarction. This could be a huge step forwards in personalized medicine.’ The journey to applying circulating microRNAs in a clinical setting may still be a long one, but the Amsterdam team believe it is worth pursuing, despite contradicting results from studies having tempered enthusiasm about circulating microRNA biomarkers. But they stress that many good candidate microRNAs have been found that show potential to improve current risk prediction and that methods to measure and analyse microRNAs have been improved in recent years. ‘Therefore, now is the time to proceed with circulating microRNA research in the cardiovascular field’, said Dr Pinto-Sietsma. ‘Only by performing large studies with standardized measurement methods and using external validation cohorts, can we assess the added value to current risk prediction models and decide if they can be used in the clinic. Large scale funding and collaboration among different research groups is essential in this regard.’ References are available as supplementary material at European Heart Journal online.
No takes yet. Share an insight, caveat, or question.
Mark Nicholls (2017) conducted an editorial in Coronary artery disease. Circulating microRNA biomarkers vs. Current risk prediction models was evaluated on Cardiovascular death prediction (AUC 0.74-0.76). Circulating microRNAs, including miR-132, miR-140-3p, and miR-210, show promise as biomarkers for predicting cardiovascular death with an area under the curve of 0.74-0.76.
Synapse has enriched 10 related papers. Consider them for comparative context: